<DOC>
	<DOC>NCT01791491</DOC>
	<brief_summary>The purpose of this study is to evaluate how well adolescent kidney transplant patients tolerate a single dose of belatacept they receive at least 6 months after transplant surgery, and how their body handles the drug.</brief_summary>
	<brief_title>Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Abatacept</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Male and Female subjects,1217 years old Receiving CNIbased maintenance immunosuppression since the time of renal transplantation in accordance with local standard of care Stable renal function, in the opinion of the investigator, with a cGFR&gt;45 mL/min/1.73m2 at the time of enrollment (per updated Schwartz Formula) Adolescent Recipients of a renal allograft from a living donor or a deceased donor at least 6 months prior to enrollment Subject must be receiving a calcineurin inhibitor (CNI)based [cyclosporine (CsA) [any formulation] or Tacrolimus (TAC)] immunosuppressive regimen Subject must be receiving adjunctive background maintenance immunosuppression with mycophenolate mofetil (MMF) or entericcoated mycophenolate sodium (ECMPS)/mycophenolic acid (MPA) Subjects may be receiving maintenance corticosteroids in accordance with the local standard of care Negative Interferon Gamma Release Assay (IGRA) such as QuantiFERONTB Gold test or TSpotTB FOCBP must have negative serum or urine pregnancy test within 24 hrs prior to start of study medication Subject must have stable estimated glomerular filtration rate (GFR) â‰¥45 mL/min/1.73m2 (updated Schwartz formula) EpsteinBarr virus (EBV) serostatus negative or unknown at time of transplant and screening History of any treated or biopsy proven acute rejection (BPAR) within 3 months prior to enrollment Subjects who have experienced more than 1 episode of acute rejection (AR) of the current allograft or any antibodymediated AR Significant proteinuria Active infection</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>